Home > Oncology > ESMO 2022 > Tumour infiltrating lymphocytes identify patients with immunogenic triple-negative breast cancer

Tumour infiltrating lymphocytes identify patients with immunogenic triple-negative breast cancer

Presented By
Dr Marleen Kok, Netherlands Cancer Institute, the Netherlands
Conference
ESMO 2022
Trial
Phase 2, BELLINI
Patients with triple-negative breast cancer (TNBC) who harbour over 40% tumour-infiltrating lymphocytes (TIL) in their tumour, respond well on neoadjuvant immune checkpoint blockade, results from the phase 2 BELLINI trial show. High TIL levels correlate with good prognosis in early TNBC [1,2]. In patients with early TNBC, neoadjuvant chemotherapy combined with PDL1- blocking agents has demonstrated an increase in pathologic complete response (pCR) and event-free survival [3,4]. However, it is not known which TNBC patients benefit from neoadjuvant anti-PD1 treatment, for which patients neoadjuvant chemotherapy can be de-escalated, nor what the additional value is from other (new generation) immune checkpoint inhibitors. Dr Marleen Kok (Netherlands Cancer Institute, the Netherlands) presented the first results of the phase 2 basket trial BELLINI (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on